Pioneering The Next Generation of Solid Tumor T Cell Immunotherapies

Focusing on improving the lives of patients with solid tumor cancers.

Developing the most mature bispecific T cell engaging platform in its class.

Advancing our COBRA™ pipeline toward the clinic.